Dear Dr. Kribbs:

Please refer to your August 21, 2001 supplemental new drug application, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, for Plavix (clopidogrel bisulfate) Tablets.

We acknowledge receipt of your submission dated February 21, 2002 that constituted a complete response to our February 20, 2002 action letter.

This supplemental new drug application provides for the use of Plavix (clopidogrel bisulfate) Tablets in Acute Coronary Syndrome.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the February 21, 2002 submitted final printed package insert. Accordingly, the supplemental application is approved effective on the date of this letter.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We note our August 29, 2001 correspondence that waived the pediatric study requirement for this application.

As requested in our February 20, 2002 approvable letter for this supplemental application, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857
If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD  20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Ms. Colleen LoCicero  
Regulatory Health Project Manager  
(301) 594-5332.

Sincerely yours,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.  
Director  
Division of Cardio-Renal Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Raymond Lipicky
2/27/02 02:39:24 PM